RLX-33

• Description:

  RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  ERK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway; Stem Cell/Wnt

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/rlx-33.html

• Concentration:

  10mM

• Purity:

  99.79

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C (C (C1) CN (CC2=CC=CO2) C1=O) NC3=CC=C (C4=NC (C5=CC=C (Cl) C=C5) =NO4) C=C3

• Molecular Formula:

  C24H19ClN4O4

• Molecular Weight:

  462.89

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]https://pubmed.ncbi.nlm.nih.gov/35594150/

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2784577-71-3